Nordson Corporation is an innovative precision technology company that engineers, manufactures and markets differentiated products and systems for precision dispensing, applying and controlling adhesives, coatings, polymers, sealants, biomaterials and other fluids. The company serves a wide variety of end markets including packaging, electronics, medical, appliances, energy, transportation, precision agriculture, building and construction and general product assembly and…
Nordson Corporation is an innovative precision technology company that engineers, manufactures and markets differentiated products and systems for precision dispensing, applying and controlling adhesives, coatings, polymers, sealants, biomaterials and other fluids. The company serves a wide variety of end markets including packaging, electronics, medical, appliances, energy, transportation, precision agriculture, building and construction and general product assembly and finishing. Nordson supports its products with extensive application expertise and direct global sales and service operations.
Nordson generates revenue by selling precision dispensing and fluid control systems, testing and inspection equipment, and surface treatment solutions to industrial and medical customers worldwide. The company markets its products primarily through a direct sales force and qualified distributors and sales representatives in more than 35 countries. Approximately 67 percent of Nordson's revenues were generated outside the United States in 2025.
The company operates through the following segments: Industrial Precision Solutions, Medical and Fluid Solutions and Advanced Technology Solutions.
• Industrial Precision Solutions: This segment delivers proprietary dispensing and material processing technology to diverse end markets such as consumer durables, non-durables, industrial, agriculture and automotive. Product line specific solutions enhance product quality and appearance while increasing line efficiency and reducing material consumption. Technologies are used for dispensing adhesives, coatings, sealants, liquids and other materials as well as processing of polymers. The segment includes key strategic product lines such as Industrial Coatings, Nonwovens, Packaging, Polymer Processing, Precision Agriculture and Product Assembly. Key strategic markets for these product lines include beverage containers and food cans, electric batteries, appliances, automotive, building and construction, composites, electronics, medical, flexible packaging, transportation and aerospace.
• Medical and Fluid Solutions: This segment includes components and device solutions for medical, life science, high-tech industrial and other diverse end markets. Engineered Fluid Solutions provides precision manual and semi-automated dispensers and highly engineered single-use plastic molded syringes, cartridges, tips and fluid connection components used in critical medical and industrial production processes. Medical Interventional Solutions offers interventional solutions for minimally invasive surgical procedures including engineered shafts, interventional delivery systems, medical tubing, balloons, balloon inflators, nitinol devices, cardiovascular cannula and biomaterial delivery. Medical Fluid Components provides proprietary single-use plastic components for drug delivery and needle-free infusion valves, single-use fluid transfer components and other related components. Surgical Solutions includes microplegia myocardial protection devices and related consumables used in cardiac surgical procedures. Key strategic markets for this segment include cardiovascular, structural heart, neurovascular, gastroenterology, drug infusion, IV and drug delivery, patient care, surgical and biopharma.
• Advanced Technology Solutions: This segment integrates proprietary product technologies into the progressive stages of a customer's production processes such as surface treatment, precisely controlled dispensing of material and pre- and post-dispense test and inspection to ensure quality. It predominantly serves customers in the semiconductor and electronics end markets. Electronics Dispense Systems provides automated dispensing systems for high-speed precise application of attachment, protection and coating fluids and related gas plasma treatment systems for cleaning and conditioning surfaces prior to dispense. Test and Inspection includes destructive and non-destructing testing technologies such as bond testers and automated optical, acoustic microscopy and x-ray inspection systems used in the semiconductor and printed circuit board industries. Products also include precision measurement and control technologies that ensure quality and reliability through in-line measurement sensors, gauges and analyzers using near-infrared, laser, x-ray, optical and nucleonic technologies as well as proprietary algorithms and software. Key strategic end markets include semiconductor packaging, printed circuit boards, flexible circuits, consumer electronics, film extrusion and converting, cable and tubing and energy storage.
Nordson maintains a leadership position in its business segments by delivering high-quality innovative products and technologies backed by global service and technical support. The company competes with many large well-established manufacturers and service providers in a competitive global marketplace. Its competitive advantages include a worldwide network of direct sales and technical resources, deep application expertise and a strong culture of innovation driven by the Nordson Business System Next growth framework and Winning Teams talent strategy.
Nordson serves a broad customer base across multiple industries and geographic regions. In 2025, no single customer accounted for ten percent or more of the company's sales. The company's customers include manufacturers in packaging, electronics, medical devices, appliances, automotive, agriculture, building and construction and general product assembly and finishing industries.
Sectors:Industrials · HealthcareSector rationaleNordson's primary business is the engineering and manufacture of precision dispensing and fluid control systems for a wide range of industrial markets, including packaging, automotive, and electronics, which falls under Industrial Machinery. A secondary sector is justified because the company has a substantial, distinct business line (Medical and Fluid Solutions) that manufactures medical interventional devices, surgical solutions, and drug delivery components sold to the healthcare industry.Industries:Industrial MachineryIndustrialsPrimaryNordson manufactures general-purpose production machinery and factory automation hardware, specifically precision dispensing and fluid control systems used in packaging, electronics, and general product assembly. Its Industrial Precision Solutions segment provides material processing technology for dispensing adhesives, coatings, and polymers to industrial operators.Medical DevicesHealthcareSecondaryThe Medical Interventional Solutions business provides therapeutic and surgical medical devices, including interventional delivery systems, balloons, and cardiovascular cannula for minimally invasive surgical procedures.Medical SuppliesHealthcareSecondaryThe Medical Fluid Components and Engineered Fluid Solutions lines manufacture medical supplies and consumables, such as single-use plastic molded syringes, cartridges, and needle-free infusion valves.Classified using BQ-MICSCIK: 0000072331
Investment Thesis
▲ Bull case
Nordson has shifted more than half of its portfolio into growth end markets such as semiconductor electronics and medical devices through its NBS Next framework. This diversification reduces reliance on slower GDP linked industrial lines and positions the company to capture secular trends like AI infrastructure and aging population demand. The shift is structural not cyclical and provides a durable foundation for above market organic growth. Management highlighted that the semiconductor portion of the ATS segment now exceeds fifty% of that business creating multiple technology levers.
Organic backlog increased eighteen% year over year reflecting broad based order entry strength across all three segments. The backlog growth is especially pronounced in the Advanced Technology Solutions segment where test and inspection and dispense businesses are both seeing rising demand. A larger order book provides visibility into future revenue and reduces the risk of near term demand softness. Management noted that the backlog conversion timeline remains normal with most orders shipping within six months supporting confidence in the second half guidance.
The acquisition of CapstanAG at nine times adjusted EBITDA adds a precision agriculture platform focused on mid tier OEM customers in North America. Capstan’s pulse width modulation technology complements Nordson’s existing Ag business which originated with the ARAG deal and allows for combined go to market efforts. The bolt on nature of the deal limits integration risk while providing immediate accretive earnings potential. Management indicated that the business could contribute roughly thirteen million dollars of annual revenue and expects further bolt on opportunities in the Ag space.
During the quarter Nordson completed a non cash pension settlement that annuitized approximately one third of its remaining U S pension obligation at a competitive discount rate. The transaction eliminated future cash outflows for that portion of the liability and improved the funded status of the remaining plan. Although a one time pretax charge of twenty four million dollars was recorded the settlement removes a long term earnings drag and enhances balance sheet strength. The move reflects proactive liability management that will support stable earnings going forward.
Free cash flow generation reached one hundred seventeen million dollars in the quarter representing a one hundred nineteen% conversion of net income excluding non cash charges. This strong cash conversion has persisted for four consecutive quarters despite accelerated revenue growth demonstrating the durability of the company’s earnings model. The excess cash enables a balanced approach to shareholder returns debt reduction and strategic reinvestment without overleveraging the balance sheet. Management highlighted that the firepower supports continued M&A activity at disciplined valuations.
Nordson has shifted more than half of its portfolio into growth end markets such as semiconductor electronics and medical devices through its NBS Next framework. This diversification reduces reliance on slower GDP linked industrial lines and positions the company to capture secular trends like AI infrastructure and aging population demand. The shift is structural not cyclical and provides a durable foundation for above market organic growth. Management highlighted that the semiconductor portion of the ATS segment now exceeds fifty% of that business creating multiple technology levers.
Organic backlog increased eighteen% year over year reflecting broad based order entry strength across all three segments. The backlog growth is especially pronounced in the Advanced Technology Solutions segment where test and inspection and dispense businesses are both seeing rising demand. A larger order book provides visibility into future revenue and reduces the risk of near term demand softness. Management noted that the backlog conversion timeline remains normal with most orders shipping within six months supporting confidence in the second half guidance.
The acquisition of CapstanAG at nine times adjusted EBITDA adds a precision agriculture platform focused on mid tier OEM customers in North America. Capstan’s pulse width modulation technology complements Nordson’s existing Ag business which originated with the ARAG deal and allows for combined go to market efforts. The bolt on nature of the deal limits integration risk while providing immediate accretive earnings potential. Management indicated that the business could contribute roughly thirteen million dollars of annual revenue and expects further bolt on opportunities in the Ag space.
During the quarter Nordson completed a non cash pension settlement that annuitized approximately one third of its remaining U S pension obligation at a competitive discount rate. The transaction eliminated future cash outflows for that portion of the liability and improved the funded status of the remaining plan. Although a one time pretax charge of twenty four million dollars was recorded the settlement removes a long term earnings drag and enhances balance sheet strength. The move reflects proactive liability management that will support stable earnings going forward.
Free cash flow generation reached one hundred seventeen million dollars in the quarter representing a one hundred nineteen% conversion of net income excluding non cash charges. This strong cash conversion has persisted for four consecutive quarters despite accelerated revenue growth demonstrating the durability of the company’s earnings model. The excess cash enables a balanced approach to shareholder returns debt reduction and strategic reinvestment without overleveraging the balance sheet. Management highlighted that the firepower supports continued M&A activity at disciplined valuations.
Persistent inflation in components resins and logistics could erode margins beyond the temporary headwind acknowledged by management if pricing power proves insufficient in competitive markets. The company noted that it is managing through selective pricing and cost actions but did not quantify the extent of offset achievable. Should input costs remain elevated for an extended period the incremental EBITDA conversion may stay below historical levels limiting profit growth despite revenue gains. This risk is especially relevant for the Industrial Precision Solutions segment where margins are already under pressure.
While management characterized the regulatory material change in medical product lines as a short term issue there is no guarantee that the transition will be completed within the expected timeframe. Any delay could prolong the margin compression and suppress growth in a segment that management aims to return to six to eight% annual expansion. The medical business also faces potential reimbursement pressure and regulatory scrutiny that could affect demand for consumables and devices. A longer than anticipated resolution would weigh on overall segment performance and distract resources from other growth initiatives.
The optimism surrounding early stage AI driven semiconductor demand may be premature given the historically cyclical nature of the industry and the potential for a downturn if capital spending slows. Nordson’s Advanced Technology Solutions segment despite diversification remains exposed to fluctuations in fab equipment and wafer processing investment. A sudden pullback in semiconductor capex could quickly reverse the strong order entry and backlog growth recently reported. The company’s reliance on test and inspection businesses which are still in an early inflection phase adds uncertainty to the durability of the current uptick.
Although management stated that the majority of backlog converts within six months a minority portion is starting to bleed into 2027 indicating that some orders have longer lead times than usual. Longer conversion periods increase the risk that orders could be cancelled or delayed if macroeconomic conditions worsen before shipment. This dynamic could create a mismatch between reported backlog and near term revenue especially for larger complex systems in the Industrial Precision Solutions segment. Investors should monitor whether the backlog composition is shifting toward more long dated projects that may not materialize as expected.
While Nordson emphasizes diversification of its customer base especially in the ATS segment there remains a possibility that certain end markets still rely on a limited number of large OEM customers. Loss of a major account or a shift in purchasing strategy by a key client could disproportionately affect sales in the affected segment. The company did not provide specific concentration metrics leaving investors to infer potential exposure from general statements. In a downturn scenario concentration risk could amplify the impact of reduced demand.
Persistent inflation in components resins and logistics could erode margins beyond the temporary headwind acknowledged by management if pricing power proves insufficient in competitive markets. The company noted that it is managing through selective pricing and cost actions but did not quantify the extent of offset achievable. Should input costs remain elevated for an extended period the incremental EBITDA conversion may stay below historical levels limiting profit growth despite revenue gains. This risk is especially relevant for the Industrial Precision Solutions segment where margins are already under pressure.
While management characterized the regulatory material change in medical product lines as a short term issue there is no guarantee that the transition will be completed within the expected timeframe. Any delay could prolong the margin compression and suppress growth in a segment that management aims to return to six to eight% annual expansion. The medical business also faces potential reimbursement pressure and regulatory scrutiny that could affect demand for consumables and devices. A longer than anticipated resolution would weigh on overall segment performance and distract resources from other growth initiatives.
The optimism surrounding early stage AI driven semiconductor demand may be premature given the historically cyclical nature of the industry and the potential for a downturn if capital spending slows. Nordson’s Advanced Technology Solutions segment despite diversification remains exposed to fluctuations in fab equipment and wafer processing investment. A sudden pullback in semiconductor capex could quickly reverse the strong order entry and backlog growth recently reported. The company’s reliance on test and inspection businesses which are still in an early inflection phase adds uncertainty to the durability of the current uptick.
Although management stated that the majority of backlog converts within six months a minority portion is starting to bleed into 2027 indicating that some orders have longer lead times than usual. Longer conversion periods increase the risk that orders could be cancelled or delayed if macroeconomic conditions worsen before shipment. This dynamic could create a mismatch between reported backlog and near term revenue especially for larger complex systems in the Industrial Precision Solutions segment. Investors should monitor whether the backlog composition is shifting toward more long dated projects that may not materialize as expected.
While Nordson emphasizes diversification of its customer base especially in the ATS segment there remains a possibility that certain end markets still rely on a limited number of large OEM customers. Loss of a major account or a shift in purchasing strategy by a key client could disproportionately affect sales in the affected segment. The company did not provide specific concentration metrics leaving investors to infer potential exposure from general statements. In a downturn scenario concentration risk could amplify the impact of reduced demand.